An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Completed
- Conditions
- Colorectal Cancer
- Registration Number
- NCT01676922
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This observational study will evaluate the use of Avastin (bevacizumab) and conventional chemotherapy in patients \>/= 70 years of age with previously untreated metastatic colorectal cancer. Data will be collected from each patient from initiation of treatment until disease progression occurs (minimum follow-up 12 months).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 256
Inclusion Criteria
- Adult patients, >/ 70 years of age
- Previously untreated metastatic colorectal cancer
- Patient considered suitable to receive chemotherapy with or without Avastin
Exclusion Criteria
- Participation in any other clinical trial or study with the exception of participation in registries
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment duration in patients receiving chemotherapy with Avastin as first-line therapy in daily clinical practice approximately 24 months
- Secondary Outcome Measures
Name Time Method Treatment duration in patients receiving chemotherapy alone as first-line therapy in daily clinical practice approximately 24 months Safety: Incidence of adverse events/adverse events of special interest approximately 24 months Clinical/demographic patient characteristics at baseline approximately 24 months Dosage/regimen approximately 24 months Correlation between Comprehensive Geriatric Assessment (CGA) scores and initial treatment approximately 24 months